Neos Therapeutics (NASDAQ:NEOS) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of Neos Therapeutics (NASDAQ:NEOS) from a sell rating to a hold rating in a research report released on Saturday morning, Zacks.com reports.

According to Zacks, “Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas. “

Shares of Neos Therapeutics stock opened at $0.69 on Friday. Neos Therapeutics has a 1 year low of $0.60 and a 1 year high of $2.15. The company has a market capitalization of $34.82 million, a P/E ratio of -1.96 and a beta of 1.29. The business has a 50 day moving average price of $0.76 and a 200 day moving average price of $1.13.

Neos Therapeutics (NASDAQ:NEOS) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.06). Neos Therapeutics had a negative return on equity of 2,087.24% and a negative net margin of 26.52%. The company had revenue of $14.49 million for the quarter. As a group, equities research analysts expect that Neos Therapeutics will post -0.23 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Goldman Sachs Group Inc. raised its holdings in Neos Therapeutics by 5.6% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,559,374 shares of the company’s stock valued at $3,865,000 after acquiring an additional 135,859 shares during the last quarter. Renaissance Technologies LLC raised its holdings in Neos Therapeutics by 63.4% in the 4th quarter. Renaissance Technologies LLC now owns 666,868 shares of the company’s stock valued at $1,007,000 after acquiring an additional 258,706 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in Neos Therapeutics in the 4th quarter valued at $184,000. Wells Fargo & Company MN raised its holdings in Neos Therapeutics by 23.0% in the 1st quarter. Wells Fargo & Company MN now owns 83,277 shares of the company’s stock valued at $63,000 after acquiring an additional 15,570 shares during the last quarter. Finally, Blair William & Co. IL acquired a new position in Neos Therapeutics in the 4th quarter valued at $25,000. Institutional investors own 39.19% of the company’s stock.

Neos Therapeutics Company Profile

Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.

Recommended Story: How a Strangle Strategy is different from a Straddle Strategy

Get a free copy of the Zacks research report on Neos Therapeutics (NEOS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.